perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2023.12.22.23300465;](https://doi.org/10.1101/2023.12.22.23300465) this version posted December 28, 2023. The copyright holder for this<br>preprint (which was not certified by peer review) is the author/funder, who has grante

It is made available under a [CC-BY 4.0 International license](http://creativecommons.org/licenses/by/4.0/) .



**NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.**

## **Prof. Dr. Deepti Vibha**

- DM (Neurology, AIIMS, New Delhi), MSc (Clinical Epidemiology, Erasmus MC,
- Netherlands)
- Professor of Neurology
- Room No.: 707, 7th Floor
- Neurosciences Centre, Department of Neurology,
- All India Institute of Medical Sciences, Ansari Nagar, New Delhi, India
- **PH:** +91-11-26594485
- **Email ID:** [deeptivibha@gmail.com](mailto:deeptivibha@gmail.com)
- 
- **Word Count:** 2942
- **Total tables:** 5
- **Total figures:** 4
- **Keywords**: Intracerebral Hemorrhage; Proteomics; Blood biomarkers; Prognosis;
- Mortality; Poor outcome.

# **Abstract**

 Early prognostication of patient outcomes in intracerebral hemorrhage (ICH) is critical for patient care. We aim to investigate protein biomarkers' role in prognosticating outcomes in ICH patients. We assessed 22 protein biomarkers using targeted proteomics in serum samples obtained from the ICH patient dataset (N=150). We defined poor outcomes as modified Rankin scale score of 3-6. We incorporated clinical variables and protein biomarkers in regression models and random forest-based machine learning algorithms to predict poor outcomes and mortality. We report Odds Ratio (OR) or Hazard Ratio (HR) with 95% Confidence Interval (CI). We used five-fold cross-validation and bootstrapping for internal validation of prediction models. We included 149 patients for 90-day and 144 patients with ICH for 180-day outcome analyses. In multivariable logistic regression, UCH-L1 (aOR 9.23; 95%CI 2.41-35.33), alpha-2-macroglobulin (5.57; 1.26- 24.59), and Serpin-A11 (9.33; 1.09-79.94) were independent predictors of 90-day poor outcome; MMP-2 (6.32; 1.82-21.90) was independent predictor of 180-day poor outcome. In multivariable Cox regression models, IGFBP-3 (aHR 2.08; 1.24-3.48) predicted 90-day and MMP-9 (1.98; 1.19-3.32) predicted 180-day mortality. Using machine learning, UCH-L1 and APO-C1 predicted 90-day mortality, and UCH-L1, MMP-9, and MMP-2 predicted 180-day mortality. Overall, random forest models outperformed regression models for predicting 180-day poor outcomes (AUC 0.89), and 90-day (AUC 0.81) and 180-day mortality (AUC 0.81). Serum biomarkers independently predicted short-term poor outcomes and mortality after ICH. Further research utilizing a multi- omics platform and temporal profiling is needed to explore additional biomarkers and refine predictive models for ICH prognosis.

# **Abbreviations**:

- ICH: Intracerebral Hemorrhage; IVH: Intraventricular hemorrhage; OR: Odds Ratio; HR:
- Hazard Ratio; CI: Confidence Interval; IQR: Interquartile range; AUC: Area Under the
- Curve; NIHSS: National Institutes of Health Stroke Scale; GCS: Glasgow Coma Scale; mRS:
- modified Rankin Scale; SBP: Systolic Blood Pressure; DBP: Diastolic Blood Pressure; TLC:
- Total Leucocyte Count; RBS: Random Blood Sugar; A2M: Alpha-2-Macroglobulin, UCH-L1:
- Ubiquitin carboxyl-terminal hydrolase isozyme L1; MMP: Matrix Metalloproteinase; APO:
- Apolipoprotein; IGFBP-3: Insulin-like growth factor-binding protein-3.

#### **Introduction**

 Intracerebral hemorrhage (ICH) comprises 10-15% of all strokes [1], with one-month mortality of 40%, rendering it the deadliest stroke subtype [2]. It is a significant healthcare challenge worldwide, and its impact is particularly pronounced in developing nations like India. Limited healthcare resources, disparities in access to care, and unique demographic and epidemiological factors exacerbate the burden of ICH in these regions [3]. Understanding factors influencing ICH patient outcomes is crucial for optimizing clinical management, risk stratification, and resource allocation. While various clinical scores exist for predicting functional outcomes and mortality in ICH [4], such as the 84 widely-used ICH score,<sup>5</sup> their accuracy for outcomes beyond hospital discharge or 30 days remains uncertain. Hence, there is a critical need for robust prediction models that integrate new predictor variables to improve ICH prognostication [5]. Serum biomarkers have emerged as promising candidates with the potential to enhance outcome prognostication in ICH patients [6]. Integrating serum biomarkers with clinical variables in prediction models may provide additional prognostic information and guide treatment decisions.

 Therefore, we undertook this study to build prognostic models using protein biomarkers to predict poor functional outcomes and mortality in ICH patients within 24 hours of symptom onset utilizing targeted proteomics, regression modeling, and machine learning approaches.

#### **Methods**

#### **Study sample**

 We used clinical and proteomic data lodged within a prospective cohort study from a collaborative effort of the Department of Neurology, All India Institute of Medical

 Sciences (AIIMS), and the Institute of Genomics and Integrative Biology in New Delhi, 101 India. The study database includes consecutive ICH patients aged  $\geq$ 18 years, recruited between 04 October 2017 and 20 March 2020 within 24 hours of symptom onset. The details of this study protocol are reported in prior publications [7,8]. We obtained written informed consent from all the recruited patients or their legally authorized representatives prior to collecting blood samples and clinical history. The study was approved by the Local Institutional Ethics Committee of AIIMS, New Delhi (Ref. No. IECPG-395/28.09.2017).

#### **Outcomes**

 We defined poor outcomes as a modified Rankin Scale (mRS) score of 3-6. Our second outcome measure was mortality. The outcomes were ascertained by a researcher blinded to clinical data using telephonic interviews at 90 and 180 days post-ICH.

#### **Blood sample collection**

 Five ml of peripheral blood sample was taken in serum vacutainer tubes from ICH 116 patients. For serum collection, it was left standing at room temperature for 30 minutes until clotted. It was then centrifuged at 3000g for 10 minutes, after which the serum was separated into cryovials. Five aliquots of each sample (100µl) were prepared and stored at -80°C until further analysis.

## **Sample preparation**

122 Ten µl of serum samples were used for protein precipitation. To 90µl of 1X Phosphate Buffer Saline (PBS), 10 µl serum was added and vortex mixed. Protein precipitation was 124 performed using pre-chilled acetone. Briefly, to 100 µl protein extract, four times volume

 of pre-chilled acetone was added, vortex mixed and centrifuged at 15000 g for 10 minutes at 4℃. The supernatant was discarded, and the protein pellets were air-dried at room

temperature and suspended in 0.1 M Tris-HCl with 8M urea, pH 8.5. Protein quantitation

- was performed using the Bradford assay.
- 

## **Reduction, Alkylation, and Trypsin Digestion**

 A total of 20 µg of protein from each sample was reduced with 25 mM of Dithiothreitol (DTT) for 30 minutes at 60℃, followed by alkylation using 55 mM of Iodoacetamide (IAA) at room temperature (in the dark) for 30 minutes. These samples were then subjected to trypsin digestion in an enzyme to substrate ratio of 1:10 (trypsin: protein) for 16-18 hours at 37℃. Finally, the tryptic peptides were vacuum dried in vacuum concentrator.

# **Peptide selection for Multiple Reaction Monitoring (MRM)-based targeted proteomics**

 Peptide selection was performed using search results from ProteinPilot [9], PeptideAtlas [10] or in-silico generated peptides of proteins using Expasy PeptideCutter tool [11]. Peptides with +2 and +3 charges were considered for MRM and for each peptide, 5-6 fragment ions were used for identification (Table S1).

#### **Multiple Reaction Monitoring (MRM) data acquisition**

 Tryptic peptides obtained after digestion were desalted using reversed phase cartridges Oasis HLB cartridge (Waters, Milford, MA) according to the following procedure: wet 147 cartridge with  $1 \times 1,000$  μl of 100% acetonitrile, equilibrate with  $1 \times 1,000$  μl of 0.1% 148 formic acid, load acidified digest, washed peptides with  $1 \times 1,000$  μl of 0.1% formic acid and elute with 1 × 1000 μl of 70% acetonitrile in 0.1% formic acid. The peptide mixture

 was dried using a vacuum centrifuge, and the peptides were resuspended in 0.1% formic acid at a final concentration of 1 μg/μl. A heavy labeled peptide for Apo A1 (QGLLPVLESF**K**; **K**=Lysine-13C6,15N2) protein was spiked-in the resolubilized plasma 153 digest at a final concentration of ng/ $\mu$ l. The targeted MRM-MS [12] analysis of the tryptic peptides was performed on a TSQ

Altis (Thermo Fisher, San Jose, CA). The instrument was equipped to an H-ESI ion source.

A spray voltage of 3.5 keV was used with a heated ion transfer tube set at a temperature

of 325°C. Chromatographic separations of peptides were performed on Vanquish UHPLC

system (Thermo Fisher, San Jose, CA).

The 10 μl of the sample was injected and peptides were loaded on an ACQUITY UPLC BEH

160 C18 column (130Å, 1.7  $\mu$ m, 2.1 mm X 100 mm, Waters) from a cooled (4 °C) autosampler

and separated with a linear gradient of water (buffer A) and acetonitrile (buffer B),

containing 0.1% formic acid, at a flow rate of 300 µl/minute in 30 minutes gradient run

with the buffer conditions given in Table S2.

 The mass spectrometer was operated in Selected Reaction Monitoring (SRM) mode. For SRM acquisitions, the first quadrupole (Q1) and the third quadrupole (Q3) were operated at 0.7 and 0.7 unit mass resolution, respectively. A dwell time of 6.175 milliseconds (ms) was chosen, and acquisitions occurred over the whole gradient of 30 minutes. Argon was used as the collision gas at a nominal pressure of 1.5 mTorr. Optimized collision energies were used for each peptide.

# **Bioinformatic and Statistical analyses**

 We analyzed the MRM-based targeted proteomics data using Skyline version 21.1 [13]. Peptide areas were spike-in normalized using a heavy labeled peptide for Apo A1 protein 174 and  $log_2$  transformed. Peptides with  $\langle 10\%$  missing values were imputed using a random-

 forest-based missing value imputation method. Non-biological experimental variations were removed through batch correction.

 Our study adhered to the Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD) guidelines [14]. We performed univariable logistic regression analysis using odds ratio (OR) and 95% confidence interval (CI) to assess poor outcomes during follow-up. Mortality rates were evaluated through Kaplan- Meier survival curves, and we constructed simple Cox proportional hazard models with hazard ratios (HR) and 95% CI. We conducted receiver operating characteristic (ROC) curve analyses and determined optimal cut-off points for each biomarker using the Youden Index (sensitivity + specificity-1).

 Regression-based ICH outcome prediction models: We developed prediction models to determine independent predictors of poor outcomes and mortality in ICH. Variables with p-value <0.1 in the univariable analysis, along with demographic variables like age and sex, were included in a backward stepwise multiple logistic regression or multiple Cox regression analyses. Multicollinearity among predictor variables was assessed using the variance inflation factor (VIF), and predictors with a VIF value exceeding 2.5 were removed from the model. We evaluated the discrimination ability using the area under the curve (AUC) or c-statistic.

 Machine Learning-based ICH outcome prediction models: We employed a random forest- based machine learning algorithm to identify additional predictors. Categorical data were encoded in binary form, while continuous data were standardized based on the population mean and standard deviation following log-normalization for skewed distributions. Train-test splits were executed in a 7:3 ratio, and random forest models with 1000 estimators were trained using the scikit-learn package. This process was repeated 1000 times, with each iteration involving a new random seed to choose the top



levels (aOR 9.33; 95%CI 1.09-79.94) as independent predictors of 90-day poor outcome;

 whereas higher MMP-2 levels (aOR 6.32, 95%CI 1.82-21.90) independently predicted 180-day poor outcome among other clinical predictors. The models had an AUC of 0.95 at 90 days and 0.92 at 180 days (Figure 1a, b and Table 3).

 Top 10 important predictors identified by random forest algorithms for 90-day outcome included NIHSS score, ICH volume, age, UCH-L1, platelet count, RBS, alpha-2- macroglobulin, TLC, serpin A11, and haptoglobin (Figure 2a). Top 10 important 231 predictors of 180-day poor outcome included NIHSS score, ICH volume, TLC, age, alpha- 2-macroglobulin, creatinine, blood urea, UCH-L1, Serpin A11, and time taken to reach hospital (Figure 2b).

#### **Mortality at 90-day and 180-day**

 Mortality at 90 days was observed in 62 (41.61%) of 149 ICH patients and at 180 days in 67 (46.53%) of 144 ICH patients. See Table 2 for clinical variables and Table S4 for protein biomarkers significantly associated with mortality in the univariable analysis 239  $(p<0.1)$ .

 Multivariable Cox regression analysis identified lower IGFBP-3 levels (aHR 2.08; 95%CI 1.24-3.48) at 90 days and lower MMP-9 levels (aHR 1.98; 95%CI 1.19-3.32) at 180 days as independent predictors of mortality. The models had an AUC of 0.83 at 90 days and 0.81 at 180 days (Figure 1c, d and Table 3).

 Top 10 predictors of 90-day mortality identified by random forest algorithms included NIHSS score, ICH volume, age, TLC, intraventricular extension, RBS, potassium, UCH-L1, hemoglobin, and APO-C1 (Figure 2c). Top 10 predictors of 180-day mortality included NIHSS score, ICH volume, age, TLC, intraventricular extension, UCH-L1, MMP-9, potassium, MMP-2, and RBS (Figure 2d).

It is made available under a [CC-BY 4.0 International license](http://creativecommons.org/licenses/by/4.0/) . perpetuity. preprint **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in medRxiv preprint doi: [https://doi.org/10.1101/2023.12.22.23300465;](https://doi.org/10.1101/2023.12.22.23300465) this version posted December 28, 2023. The copyright holder for this

#### **Internal validation of prediction models**

 Five-fold cross-validation and bootstrapping revealed that prediction models constructed with the random forest algorithm outperformed multivariable logistic and Cox regression in predicting poor outcomes at 180-day and mortality at both time points. However, there was a marginal difference in the mean AUC values of regression models and random forest models for predicting 90-day poor outcomes (Table 4, Figure S1).

#### **Validation of previous ICH prediction models**

 We validated previously published ICH prediction scores, including ICH score, MICH score, ICH-FOS score, and ICH-GS score. These scores had AUCs ranging from 0.80 to 0.86 260 for predicting poor outcomes at 90 days and from 0.76 to 0.84 at 180 days. For mortality prediction, the AUCs ranged from 0.78 to 0.81 at 90 days and from 0.76 to 0.80 at 180 days. Adding biomarkers to the prediction models in this study improved the prediction of poor outcomes compared to previous models, but no difference was noted in models predicting mortality (Table 5).

#### **Interaction network and enrichment analyses**

 In univariable analysis, we analyzed a protein network of 10 biomarkers linked to poor outcomes and mortality post-ICH. This network featured ten biomarkers (nodes) with eight interactions (edges), including six highly connected biomarkers. MMP-9 displayed 270 the highest degree of interaction, connecting with four other proteins. In our network, 7 271 out of 8 interactions had a score exceeding 0.80, with the most robust interaction score of 0.96 between MMP-2 and IGFBP-3 (Figure S2). The significant pathways encompassed negative regulation of catalytic activity, protein metabolic processes, extracellular space, and extracellular matrix disassembly (Table S5).

#### **Discussion**

277 Our analysis reaffirms the relevance of established clinical variables in predicting poor outcomes and mortality in ICH, including age, GCS score, ICH volume, NIHSS score, and various laboratory investigations, underscoring their significance in clinical practice [16,17]. Furthermore, our analyses of 22 protein biomarkers and clinical features noted in 24 hours post-ICH revealed UCH-L1, alpha-2-macroglobulin, Serpin A11, and MMP-2 as independent predictors of poor outcome. IGFBP-3 and MMP-9 independently predicted mortality following ICH. Machine learning-based random forest models identified additional predictors, including haptoglobin for poor outcomes and UCH-L1, APO-C1, and MMP-2 for mortality prediction. Integrating protein biomarkers to clinical 286 prediction models may enhance the precision of risk assessment and resource allocation in stroke prevention programs [18], promoting more efficient resource allocation targeting individuals most likely to develop ICH.

 Our study reveals inconsistent optimal values for sensitivity and specificity in biomarker cutoffs from univariable analyses (Tables S3 and S4). This emphasizes the need to consider multiple biomarkers and their cutoff values for improved accuracy and reliability in ICH outcome prediction.

 This study, conducted in a tertiary care center in India, holds particular significance due to the diverse demographic, genetic, and environmental factors unique to the Indian population. Understanding stroke in this context contributes to a more holistic understanding of the disease and its multifaceted risk factors, which is vital as India and many other developing nations face an increasing burden of stroke [19]. These findings can be pivotal in shaping stroke treatment and outcome prognostication strategies unique to India and similar resource-limited settings.

 UCH-L1's association with poor outcomes in ICH suggests its potential as an early neurological damage marker [20]. Alpha-2-macroglobulin's role in predicting poor outcomes in ICH, previously unexplored, may relate to its involvement in protease inhibition and inflammation regulation [21]. Serpin A11's anti-inflammatory and anti- fibrotic properties may signify a response to mitigate damage after ICH [22]. IGFBP-3's downregulation in ICH could reflect a compromised injury response [23]. The role of APO-C1 and haptoglobin in ICH prognostication, reported for the first time in our study, requires further investigation.

 MMP-2 and MMP-9, implicated in tissue remodeling and inflammation [24], highlight extracellular matrix dynamics in ICH pathogenesis [25]. Indeed, our network and enrichment analyses underscored MMP-9's central role in ICH pathophysiology (Figure S2), particularly its involvement in extracellular matrix-related pathways influencing ICH outcomes (Table S6) [25]. MMP-9's association with short-term mortality but not poor functional outcomes aligns with previous Indian population findings [26], suggesting potential for MMP-9 inhibition as a neuroprotective strategy in ICH [27].

 Prediction models are limited by the risk of overfitting to the training data, potentially compromising their generalizability. Cross-validation and bootstrapping address this by assessing model performance across different data subsets and testing stability through resampling. We, therefore, internally validated our findings through five-fold cross- validation and bootstrapping, demonstrating that random forest models consistently outperformed regression models in predicting 180-day poor outcome and 90-day and 180-day mortality, as evidenced by higher AUC values (Table 4). This suggests that machine learning algorithms, with their ability to capture complex interactions and patterns, offer a valuable tool for enhancing prognostic accuracy in ICH [28,29].

 We also validated the performance of previously published prediction scores for ICH outcomes (Table S5). Our study, demonstrated higher AUC values for poor outcome predictions compared to the existing prediction scores. This suggests that integrating novel protein biomarkers and clinical features in our model enhances the precision of risk assessment for ICH outcomes.

 The choice of outcomes in this study emphasizes the importance of patient-reported outcome measures (PROMs) and quality of life in stroke research and care [30]. While many clinical trials prioritize mortality as the primary outcome, it's essential to acknowledge that survival alone may not fully represent the patient's overall well-being or quality of life [31]. Rankin 4-5 indicates significant disability, and for many patients, this level of impairment can be as debilitating as death itself. Rankin 3 signifies moderate disability that can significantly affect a patient's independence and quality of life. By consolidating mRS scores 3-6, our study essentially encompasses all patients experiencing death or significant disability.

 Compared to previous studies, our study has several strengths. Firstly, we utilized a targeted proteomics approach, specifically multiple reaction monitoring, for precise and sensitive measurement of protein biomarkers. Secondly, we recruited patients within the 24-hour window, a critical period for stroke management, allowing earlier biomarker assessment than prior studies [26,32]. Thirdly, our study had minimal loss to follow-up (<5%).

 However, our study also has several limitations. Firstly, the small sample size warrants external validation of these biomarkers in adequately powered studies. However, we internally validated our dataset and obtained consistent AUCs across the outcome measures. Secondly, our study only included patients from a single center, limiting its generalizability. Thirdly, focusing on a 24-hour time window may not capture the full ICH

 progression, necessitating earlier biomarker measurements [33,34] and exploring temporal changes. Lastly, we provided relative quantification data for protein biomarkers, suggesting the need for obtaining absolute quantification values in future studies.

#### **Conclusion**

These data reflect outcomes in developing nations underscoring the potential of serum

- biomarkers, in conjunction with clinical variables, to enhance outcome prediction in ICH
- patients. Biomarkers like UCH-L1, alpha-2-macroglobulin, Serpin A11, MMP-2, IGFBP-3,
- and MMP-9 showed strong associations with outcomes, improving model accuracy. With
- better performance of random forest-based machine learning models, proteomic data
- holds promise for ICH prognostication. Future research should examine temporal profiles
- of these biomarkers in larger cohorts and explore additional pathways using multi-omics
- platforms to refine predictive models for ICH prognosis.
- 

#### **Competing Interests**

- The authors have declared that no competing interests exist.
- 

# **Acknowledgements**

- S. Misra was a DST-INSPIRE Fellow supported by Department of Science and Technology,
- Government of India.

#### **Study Funding**

This study was supported in part by the AIIMS Intramural Research Grant (F. No. 8-

762/A-762/2019/RS).

# **Ethics Approval**

 The study was approved by the local institutional ethics committee of AIIMS, New Delhi (Ref. No. IECPG-395/28.09.2017). We obtained written informed consent from all the recruited patients or their legally authorized representatives prior to collecting blood samples and clinical history.

 **Author Contributions:** DV conceptualized the idea of this research topic, helped design the clinical methodology, and supervised each step of execution of this study. SM primarily conducted each step of this study ranging from blood sample collection, processing, proteomic experimentation, statistical and proteomic data analysis, building prediction models, results interpretation, and manuscript writing. YK conducted the machine learning analysis. SSG supervised the proteomic experimentation and its data analysis. SM and PS conducted the proteomic experiments and data analysis. ZR contributed in conducting the proteomic experimentations in the study. MN contributed in patient sample collection and processing. AK, PK, and NKM helped in statistical data analysis. DV, PA, AKS, AKP, DM, and KP aided in patient recruitment for this study. All authors contributed to the article and approved the submitted version.

perpetuity. preprint **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in medRxiv preprint doi: [https://doi.org/10.1101/2023.12.22.23300465;](https://doi.org/10.1101/2023.12.22.23300465) this version posted December 28, 2023. The copyright holder for this

# It is made available under a [CC-BY 4.0 International license](http://creativecommons.org/licenses/by/4.0/) .

#### **References**

- 1. Tsao CW, Aday AW, Almarzooq ZI, Anderson CAM, Arora P, Avery CL, et al. Heart Disease and Stroke Statistics-2023 Update: A Report From the American Heart Association. Circulation. 2023;147: e93–e621. doi:10.1161/CIR.0000000000001123
- 2. An SJ, Kim TJ, Yoon B-W. Epidemiology, Risk Factors, and Clinical Features of Intracerebral Hemorrhage: An Update. J Stroke. 2017;19: 3–10. doi:10.5853/jos.2016.00864
- 3. Pandian JD, Padma Srivastava MV, Aaron S, Ranawaka UK, Venketasubramanian N, Sebastian IA, et al. The burden, risk factors and unique etiologies of stroke in South-East Asia Region (SEAR). Lancet Reg Health Southeast Asia. 2023;17: 100290. doi:10.1016/j.lansea.2023.100290
- 4. Gregório T, Pipa S, Cavaleiro P, Atanásio G, Albuquerque I, Chaves PC, et al. Prognostic models for intracerebral hemorrhage: systematic review and meta-analysis. BMC Med Res Methodol. 2018;18: 145. doi:10.1186/s12874-018-0613-8
- 5. Wartenberg KE, Hwang DY, Haeusler KG, Muehlschlegel S, Sakowitz OW, Madžar D, et al. Gap Analysis Regarding Prognostication in Neurocritical Care: A Joint Statement from the German Neurocritical Care Society and the Neurocritical Care Society. Neurocrit Care. 2019;31: 231–244. doi:10.1007/s12028-019-00769-6
- 6. Troiani Z, Ascanio L, Rossitto CP, Ali M, Mohammadi N, Majidi S, et al. Prognostic Utility of Serum Biomarkers in Intracerebral Hemorrhage: A Systematic Review. Neurorehabil Neural Repair. 2021;35: 946–959. doi:10.1177/15459683211041314
- 7. Misra S, Singh P, Sengupta S, Kushwaha M, Rahman Z, Bhalla D, et al. Subtyping strokes using blood-based biomarkers: A proteomics approach. medRxiv; 2023. p. 2023.06.10.23291233. doi:10.1101/2023.06.10.23291233
- 8. Misra S, Singh P, Nath M, Bhalla D, Sengupta S, Kumar A, et al. Blood-based protein biomarkers for the diagnosis of acute stroke: A discovery-based SWATH-MS proteomic approach. Front Neurol. 2022;13: 989856. doi:10.3389/fneur.2022.989856
- 423 9. Seymour SL, Hunter CL. ProteinPilot™ Software overview. : 5.
- 10. Desiere F, Deutsch EW, King NL, Nesvizhskii AI, Mallick P, Eng J, et al. The PeptideAtlas project. Nucleic Acids Res. 2006;34: D655-658. doi:10.1093/nar/gkj040
- 11. Wilkins MR, Gasteiger E, Bairoch A, Sanchez JC, Williams KL, Appel RD, et al. Protein identification and analysis tools in the ExPASy server. Methods Mol Biol. 1999;112: 531–552. doi:10.1385/1-59259-584-7:531

# 12. Zhang H, Liu Q, Zimmerman LJ, Ham A-JL, Slebos RJC, Rahman J, et al. Methods for peptide and protein quantitation by liquid chromatography-multiple reaction



 monitoring mass spectrometry. Mol Cell Proteomics. 2011;10: M110.006593. doi:10.1074/mcp.M110.006593 13. MacLean B, Tomazela DM, Shulman N, Chambers M, Finney GL, Frewen B, et al. Skyline: an open source document editor for creating and analyzing targeted proteomics experiments. Bioinformatics. 2010;26: 966–968. doi:10.1093/bioinformatics/btq054 14. Collins GS, Reitsma JB, Altman DG, Moons KGM, TRIPOD Group. Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD statement. The TRIPOD Group. Circulation. 2015;131: 211– 219. doi:10.1161/CIRCULATIONAHA.114.014508 15. Perez-Riverol Y, Csordas A, Bai J, Bernal-Llinares M, Hewapathirana S, Kundu DJ, et al. The PRIDE database and related tools and resources in 2019: improving support for quantification data. Nucleic Acids Res. 2019;47: D442–D450. doi:10.1093/nar/gky1106 16. Hemphill JC, Bonovich DC, Besmertis L, Manley GT, Johnston SC. The ICH score: a simple, reliable grading scale for intracerebral hemorrhage. Stroke. 2001;32: 891– 897. doi:10.1161/01.str.32.4.891 17. Morotti A, Phuah C-L, Anderson CD, Jessel MJ, Schwab K, Ayres AM, et al. Leukocyte Count and Intracerebral Hemorrhage Expansion. Stroke. 2016;47: 1473–1478. doi:10.1161/STROKEAHA.116.013176 18. Mishra NK, Khadilkar SV. Stroke program for India. Ann Indian Acad Neurol. 2010;13: 28–32. doi:10.4103/0972-2327.61273 19. GBD 2016 Lifetime Risk of Stroke Collaborators, Feigin VL, Nguyen G, Cercy K, Johnson CO, Alam T, et al. Global, Regional, and Country-Specific Lifetime Risks of Stroke, 1990 and 2016. N Engl J Med. 2018;379: 2429–2437. doi:10.1056/NEJMoa1804492 20. Yu W-H, Wang W-H, Dong X-Q, Du Q, Yang D-B, Shen Y-F, et al. Prognostic significance of plasma copeptin detection compared with multiple biomarkers in intracerebral hemorrhage. Clin Chim Acta. 2014;433: 174–178. doi:10.1016/j.cca.2014.03.014 21. Vandooren J, Itoh Y. Alpha-2-Macroglobulin in Inflammation, Immunity and Infections. Front Immunol. 2021;12: 803244. doi:10.3389/fimmu.2021.803244 22. Yan B, Luo L, Liu L, Wang Z, Chen R, Wu Y, et al. Serpin family proteins as potential biomarkers and therapeutic drugs in stroke: A systematic review and meta- analysis on clinical/preclinical studies. CNS Neurosci Ther. 2023;29: 1738–1749. doi:10.1111/cns.14205 23. Siddiqui EM, Mehan S, Bhalla S, Shandilya A. Potential role of IGF-1/GLP-1 signaling activation in intracerebral hemorrhage. Curr Res Neurobiol. 2022;3: 100055. doi:10.1016/j.crneur.2022.100055

perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2023.12.22.23300465;](https://doi.org/10.1101/2023.12.22.23300465) this version posted December 28, 2023. The copyright holder for this<br>preprint (which was not certified by peer review) is the author/funder, who has grante

It is made available under a [CC-BY 4.0 International license](http://creativecommons.org/licenses/by/4.0/) .

 24. Misra S, Talwar P, Kumar A, Kumar P, Sagar R, Vibha D, et al. Association between matrix metalloproteinase family gene polymorphisms and risk of ischemic stroke: A systematic review and meta-analysis of 29 studies. Gene. 2018;672: 180–194. doi:10.1016/j.gene.2018.06.027

- 25. Li H, Ghorbani S, Ling C-C, Yong VW, Xue M. The extracellular matrix as modifier of neuroinflammation and recovery in ischemic stroke and intracerebral hemorrhage. Neurobiol Dis. 2023;186: 106282. doi:10.1016/j.nbd.2023.106282
- 26. Sagar R, Kumar A, Verma V, Yadav AK, Raj R, Rawat D, et al. Incremental Accuracy of Blood Biomarkers for Predicting Clinical Outcomes After Intracerebral Hemorrhage. J Stroke Cerebrovasc Dis. 2021;30: 105537. doi:10.1016/j.jstrokecerebrovasdis.2020.105537
- 27. Dang B, Duan X, Wang Z, He W, Chen G. A Therapeutic Target of Cerebral Hemorrhagic Stroke: Matrix Metalloproteinase- 9. Curr Drug Targets. 2017;18: 1358–1366. doi:10.2174/1389450118666170427151657
- 28. Guo R, Zhang R, Liu R, Liu Y, Li H, Ma L, et al. Machine Learning-Based Approaches for Prediction of Patients' Functional Outcome and Mortality after Spontaneous Intracerebral Hemorrhage. J Pers Med. 2022;12: 112. doi:10.3390/jpm12010112
- 29. Fernandez-Lozano C, Hervella P, Mato-Abad V, Rodríguez-Yáñez M, Suárez-Garaboa S, López-Dequidt I, et al. Random forest-based prediction of stroke outcome. Sci Rep. 2021;11: 10071. doi:10.1038/s41598-021-89434-7
- 30. Reeves M, Lisabeth L, Williams L, Katzan I, Kapral M, Deutsch A, et al. Patient- Reported Outcome Measures (PROMs) for Acute Stroke: Rationale, Methods and Future Directions. Stroke. 2018;49: 1549–1556. doi:10.1161/STROKEAHA.117.018912
- 31. Heneghan C, Goldacre B, Mahtani KR. Why clinical trial outcomes fail to translate into benefits for patients. Trials. 2017;18: 122. doi:10.1186/s13063-017-1870-2
- 32. Ebinger M, Ipsen N, Leonards CO, Empl L, Hanne L, Liman T, et al. Circulating insulin-like growth factor binding protein-3 predicts one-year outcome after ischemic stroke. Exp Clin Endocrinol Diabetes. 2015;123: 461–465. doi:10.1055/s-0035-1554632
- 33. Misra S, Kumar A, Kumar P, Yadav AK, Mohania D, Pandit AK, et al. Blood-based protein biomarkers for stroke differentiation: A systematic review. Proteomics Clin Appl. 2017;11. doi:10.1002/prca.201700007
- 34. Misra S, Montaner J, Ramiro L, Arora R, Talwar P, Nath M, et al. Blood biomarkers for the diagnosis and differentiation of stroke: A systematic review and meta-analysis. Int J Stroke. 2020;15: 704–721. doi:10.1177/1747493020946157
- 35. Cho D-Y, Chen C-C, Lee W-Y, Lee H-C, Ho L-H. A new Modified Intracerebral Hemorrhage score for treatment decisions in basal ganglia hemorrhage--a randomized trial. Crit Care Med. 2008;36: 2151–2156.
- doi:10.1097/CCM.0b013e318173fc99

perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2023.12.22.23300465;](https://doi.org/10.1101/2023.12.22.23300465) this version posted December 28, 2023. The copyright holder for this<br>preprint (which was not certified by peer review) is the author/funder, who has grante

It is made available under a [CC-BY 4.0 International license](http://creativecommons.org/licenses/by/4.0/) .

- 36. Ji R, Shen H, Pan Y, Wang P, Liu G, Wang Y, et al. A novel risk score to predict 1-year functional outcome after intracerebral hemorrhage and comparison with existing scores. Crit Care. 2013;17: R275. doi:10.1186/cc13130
- 37. Ruiz-Sandoval JL, Chiquete E, Romero-Vargas S, Padilla-Martínez JJ, González-
- Cornejo S. Grading scale for prediction of outcome in primary intracerebral
- hemorrhages. Stroke. 2007;38: 1641–1644. doi:10.1161/STROKEAHA.106.478222

#### **Figure Legends**

- **Figure 1:** ROC curves to predict (a) 90-day poor outcome, (b) 180-day poor outcome, (c)
- 90-day mortality, and (d) 180-day mortality in multivariable analysis of ICH patients.

 **Figure 2:** Absolute mean Shapely values calculated for random forest-based machine learning algorithms to predict (a) 90-day poor outcome, (b) 180-day poor outcome, (c)

90-day mortality, and (d) 180-day mortality in ICH.

- **Figure 3:** ROC curves for five-fold cross validation of multivariable regression models to
- predict (a) 90-day poor outcome, (b) 180-day poor outcome, (c) 90-day mortality, and (d) 180-day mortality in ICH.

 **Figure 4:** Protein-protein interaction network analysis of significant protein biomarkers that can predict poor functional outcome and mortality after ICH using the Cytoscape software. The colour of nodes and edges represents the degree of interaction and interaction score.



**Table 1:** Baseline characteristics and univariable analyses of poor outcomes at 90-day and 180-day after intracerebral hemorrhage.





a: Variables represented as Median (IQR), b: Variables represented as frequency (percentage).



**Table 2:** Baseline characteristics and univariable analyses of mortality at 90-day and 180-day after intracerebral hemorrhage.





a: Variables represented as Median (IQR), b: Variables represented as frequency (percentage).



# **Table 3:** Multivariable prediction models to predict poor outcome and mortality after Intracerebral Hemorrhage



90-day poor outcome adjusted for age, gender, any surgical procedure, CCB, diuretic, heavy alcohol, low education, ICH volume, IVH, Deep ICH, NIHSS, RBS, TLC, HP,

UCH-L1, A2M, and Serpin A11.

180-day poor outcome adjusted for age, gender, any surgical procedure, diabetes, moderate alcohol, low education, ICH volume, IVH, NIHSS, TLC, RBS, hemoglobin,

blood urea, creatinine, A2M, MINPP-1, MMP-2, and UCH-L1.

90-day mortality adjusted for age, gender, diabetes, heavy alcohol, ICH volume, IVH, NIHSS, TLC, RBS, blood urea, creatinine, APO-C1, IGFBP3, and UCH-L1.

180-day mortality adjusted for age, gender, diabetes, heavy alcohol, ICH volume, IVH, NIHSS, TLC, RBS, blood urea, creatinine, APO-C1, UCH-L1, and MMP-9.

**Table 4:** Five-fold cross validation and bootstrapping for internal validation of prediction

models





**Table 5:** Validation of previously published ICH prediction scores.

**Abbreviations**- ICH: Intracerebral hemorrhage; MICH- modified Intracerebral hemorrhage; ICH-FOS: Intracerebral hemorrhage- Functional Outcome Score; ICH-GS: intracerebral hemorrhage Grading Scale; AUC: Area Under the Curve; CI: Confidence Interval.

The present study's AUCs include the internally validated 5-fold cross validation AUC values from logistic regression.

**ICH score**: Glasgow coma scale (GCS)  $(15-13=0; 12-5=1; 4-3=2)$ , ICH volume  $( $30 \text{ cm}^3 = 0; \geq 30 \text{ cm}^3 = 1$ ), presence of intraventricular hemorrhage (IVH) (no = 0;$  $yes = 1$ ), infratentorial origin (no = 0; yes = 1), age (<80 = 0; ≥80 = 1).

**MICH score**: GCS (15-13= 0; 12-5= 1; 4-3= 2), ICH volume (≤20 cm<sup>3</sup> = 0; 21-50 cm<sup>3</sup> = 1; ≥51 cm<sup>3</sup> = 2), presence of IVH or hydrocephalus (no = 0; yes = 1).

**ICH-FOS score**: age (≤59 = 0; 60-69 = 1; 70-79 = 2; ≥80 = 4), NIH Stroke Scale (NIHSS) (0-5 = 0; 6-10 = 2; 11-15 = 3; 16-20 = 4; ≥21 = 5), GCS (15-13 = 0; 12-9 = 1; 8- 3 = 2), admission glucose (≤11.0 mmol/L = 0; ≥11.1 mmol/L = 1), ICH volume for supratentorial origin (<40 cm<sup>3</sup> = 0; 40-70 cm<sup>3</sup> = 2; >70 cm<sup>3</sup> = 2), ICH volume for infratentorial origin (<10 cm<sup>3</sup> = 0; 10-20 cm<sup>3</sup> = 2; >20 cm<sup>3</sup> = 2), IVH (no = 0; yes = 1).

**ICH-GS score**: age  $(45 = 1; 45-64 = 2; \ge 65 = 3)$ , GCS  $(15-13 = 1, 12-9 = 2, 8-3 = 3)$ , ICH location (supratentorial = 1; infratentorial = 2), ICH volume (for supratentorial origin: <40 cm<sup>3</sup> = 1; 40-70 cm<sup>3</sup> = 2; >70 cm<sup>3</sup> = 3; for infratentorial origin: <10 cm<sup>3</sup> = 1; 10-20 cm<sup>3</sup> = 2; >20 cm<sup>3</sup> = 3).







